Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared Mostafa Faisal Mohammed Saleh’s post on LinkedIn, adding:
”Honored to contribute to this review published in Current Oncology MDPI, evaluating a decade of evidence on second or salvage autologous stem cell transplantation in relapsed multiple myeloma.
This work reinforces that ASCT2 remains a clinically meaningful, risk-adapted option for selected patients, particularly those with prolonged first remission and chemosensitive relapse, even in the era of CAR-T and bispecific antibodies.
Grateful to collaborate with distinguished colleagues Marwa Nassar, Nourah Alzaidy, Amr Hanbali, Mahmoud Aljurf, and Mostafa Faisal Mohammed Saleh.
It was a privilege to work together on this important analysis.”
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our recent review just out in Current Oncology: ASCT2 in relapsed MM (2016 – 2026) across14 key studies.
Feasible and safe: NRM 1–4% (day 100–1y) across large registries (n=305–975).
Median PFS 9.8–30.2 mo; OS ~30 to >80 mo depending on risk.
Interval ≥24 mo from ASCT1 = strongest predictor → PFS 17–45 mo; OS >60–80 mo in favorable subsets.
Maintenance matters: lenalidomide PFS 41 vs 21.6 mo; carfilzomib-dex TTP 25.1 vs 16.7 mo.
Phase III GMMG ReLApsE: no PFS/OS superiority (20.5 vs 19.3 mo; OS 67.1 vs 62.7) → selection is key.
In the CAR-T/bispecific era, ASCT2 = risk-adapted consolidation or bridge — not routine salvage.”
Title: Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review
Authors: Marwa Nassar, Nourah Alzaidy, Abdulrahman Nasiri, Amr Hanbali, Mahmoud A. Aljurf, Mostafa F. Mohammed Saleh
Read the Full Article on Current Oncology․
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda